BlackRock Health Sciences Term Trust Stock Price, News & Analysis

BlackRock Health Sciences Term Trust (NYSE: BMEZ) is a closed-end fund that trades on the New York Stock Exchange. It is part of the finance and insurance sector and is classified within securities and commodity exchanges. The fund is managed by BlackRock Advisors, LLC, which is described in multiple press releases as the investment advisor to BlackRock closed-end funds.

The fund was previously known as BlackRock Health Sciences Trust II. According to a BlackRock press release, effective on April 5, 2023, BlackRock Health Sciences Trust II changed its name to BlackRock Health Sciences Term Trust. The fund is included among BlackRock’s health sciences and healthcare-related investment products, as highlighted in a conference call announcement that referenced BlackRock Health Sciences Term Trust alongside BlackRock Health Sciences Trust and BlackRock Health Sciences Opportunities Fund.

BlackRock Health Sciences Term Trust is described in the Polygon data as a closed-ended management investment company. That description states that the investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Polygon description also states that the trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.

In several BlackRock press releases, the fund is grouped with other BlackRock closed-end funds that have managed distribution plans. These plans are described as supporting a level distribution of income, capital gains and/or return of capital. Under the plans, each fund distributes all available investment income to shareholders, consistent with its investment objectives and as required by the Internal Revenue Code of 1986, as amended. If sufficient income is not available for a monthly distribution, the fund may distribute long-term capital gains and/or return of capital in order to maintain its stated distribution approach.

BlackRock Health Sciences Term Trust has been the subject of multiple announcements regarding its distribution rate and structure. In a series of press releases, BlackRock explained that the fund’s Board of Trustees approved changes to the managed distribution plan. One update described a move to pay monthly distributions at an annual rate calculated as a percentage of the fund’s rolling average daily net asset value. A later update described a change from a floating rate distribution to a level rate distribution at a stated monthly rate. These changes were described as seeking to enhance distribution stability and to manage the proportion of public and private investments, while maintaining a distribution rate that the Board considered competitive and offering the potential to grow the fund’s net asset value.

The fund has also conducted tender offers for its common shares. Press releases describe tender offers authorized by the Board of Trustees to repurchase a portion of the fund’s outstanding common shares at a price equal to a stated percentage of net asset value per share. One tender offer was for up to 2.5% of outstanding common shares, and a later tender offer was for up to 40% of outstanding common shares. In the tender offer for up to 40% of outstanding common shares, the fund announced the commencement, expiration and pricing dates, and later reported preliminary and final results. The tender offer was described as undersubscribed, and the fund stated that it would purchase all shares properly tendered from all tendering shareholders, with payment expected within a specified number of business days after the expiration date.

In connection with these corporate actions, BlackRock and the fund have emphasized that shareholders should not draw conclusions about investment performance solely from the amount or terms of distributions or tender offers. The press releases state that the amount distributed per share under a managed distribution plan is subject to change at the discretion of the fund’s Board, and that each plan is subject to ongoing review to determine whether it should be continued, modified or terminated. The Board may amend, suspend or terminate a plan if it deems such actions to be in the best interest of the fund or its shareholders.

BlackRock’s descriptions of its role note that BlackRock acts as a fiduciary to investors and is a provider of financial technology, and that it manages closed-end funds such as BlackRock Health Sciences Term Trust with the aim of helping investors pursue financial well-being. Regulatory filings and further details about the fund are described in the press releases as being available through the U.S. Securities and Exchange Commission’s website and BlackRock’s own channels.

Business focus and investment objective

According to the Polygon description, BlackRock Health Sciences Term Trust is a closed-ended management investment company with an investment objective of providing total return through a combination of current income and long-term capital appreciation. The same description states that, under normal market conditions, the trust seeks to invest at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry. This description provides the clearest available statement of the fund’s intended asset allocation and sector exposure.

BlackRock’s press materials identify the fund as part of a group of health sciences and healthcare-related funds, and BlackRock has organized investor communications, such as a healthcare and megatrend update call, that highlight BlackRock Health Sciences Term Trust together with other health sciences funds. These communications indicate that the fund is used within BlackRock’s broader platform to provide investors with access to themes related to health sciences and healthcare investing, while the Polygon description focuses on energy and natural resources exposure. Both descriptions are sourced and are presented here as stated without reconciling them.

Distributions and managed distribution plan

BlackRock has issued multiple press releases explaining how BlackRock Health Sciences Term Trust’s managed distribution plan operates. The fund pays regular distributions to shareholders, and the Board of Trustees has adjusted the distribution formula over time. One press release states that, effective with a specified distribution, each of the referenced funds, including BMEZ, would pay monthly distributions at an annual rate of 6% of the fund’s 12‑month rolling average daily net asset value, calculated a set number of business days prior to the declaration date. Another press release states that the fund would change from a floating rate distribution to a level rate distribution at a stated monthly rate per share.

BlackRock’s communications explain that if sufficient investment income (including net investment income and short‑term capital gains) is not available for a monthly distribution, the fund will distribute long‑term capital gains and/or return of capital to maintain the distribution level. In certain notices, BlackRock has provided estimates of the sources of distributions, indicating the proportions attributable to net income, net realized short‑term gains, net realized long‑term gains, and return of capital for specific periods. For BlackRock Health Sciences Term Trust, these estimates have at times indicated that distributions were composed entirely of return of capital for the periods referenced, with explanatory language that a return of capital may occur when some or all of the shareholder’s investment is paid back and that such distributions do not necessarily reflect investment performance.

Corporate actions and shareholder programs

BlackRock Health Sciences Term Trust has been included in broader programs affecting multiple BlackRock closed-end funds. One press release describes tender offers for several funds, including BMEZ, for up to 2.5% of outstanding common shares, with the tender offers reported as oversubscribed and purchases made on a pro rata basis. Another set of press releases details agreements among BlackRock, the fund and Saba Capital Management, L.P. Under these agreements, the Board of Trustees of BlackRock Health Sciences Term Trust approved a tender offer to repurchase 40% of its outstanding common shares at a price equal to 99.5% of net asset value per share, with the tender offer expected to commence and close on specified dates. The agreements also describe Saba’s commitments regarding tendering its shares, withdrawing shareholder proposals and complying with standstill covenants for a defined period.

Subsequent announcements from the fund provide the commencement, expiration and pricing dates for the 40% tender offer, as well as preliminary and final results. The fund reported that the tender offer was undersubscribed and that all properly tendered shares would be purchased. These communications emphasize that the terms and conditions of the tender offer are set forth in documents filed with the SEC, including an offer to purchase and related materials, and that shareholders can obtain these documents from the SEC’s website.

Regulatory disclosures and information access

Across its press releases, BlackRock notes that annual and semi‑annual reports and other regulatory filings of BlackRock Health Sciences Term Trust with the SEC are accessible on the SEC’s website and on BlackRock’s website. The fund’s performance data and other information are described as being updated on a monthly basis in the closed‑end funds section of BlackRock’s site, along with other material information as necessary. The press releases also state that references to BlackRock’s website are intended to allow public access to information regarding the fund and are not intended to incorporate the website content into the press releases.

FAQs about BlackRock Health Sciences Term Trust (BMEZ)

• What is BlackRock Health Sciences Term Trust (BMEZ)?
  BlackRock Health Sciences Term Trust (BMEZ) is a closed-end management investment company that trades on the New York Stock Exchange. It is managed by BlackRock Advisors, LLC and is categorized in the finance and insurance sector under securities and commodity exchanges.
• What was the former name of BMEZ?
  According to a BlackRock press release, the fund was previously named BlackRock Health Sciences Trust II. Effective on April 5, 2023, BlackRock Health Sciences Trust II changed its name to BlackRock Health Sciences Term Trust.
• What is the stated investment objective of the trust?
  The Polygon description states that the investment objective is to provide total return through a combination of current income and long‑term capital appreciation. This objective is presented as the core goal of the trust.
• How does the Polygon description characterize the fund’s investment strategy?
  The Polygon description states that, under normal market conditions, the trust seeks to invest at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.
• How are distributions from BMEZ determined?
  BlackRock press releases explain that BMEZ operates under a managed distribution plan approved by its Board of Trustees. At different times, the fund has paid monthly distributions based on a percentage of its rolling average daily net asset value or at a specified level monthly rate, with the Board retaining discretion to change the rate.
• What are the possible sources of BMEZ’s distributions?
  In its communications, BlackRock states that distributions may come from net investment income, net realized short‑term capital gains, net realized long‑term capital gains, and return of capital. If sufficient income is not available, the fund may distribute long‑term capital gains and/or return of capital to maintain its distribution level.
• Has BMEZ conducted tender offers for its shares?
  Yes. Press releases describe tender offers for up to 2.5% of outstanding common shares and a separate tender offer for up to 40% of outstanding common shares. The 40% tender offer was reported as undersubscribed, and the fund stated that it would purchase all properly tendered shares.
• How are tender offer prices for BMEZ determined in the described programs?
  In the tender offers discussed in the press releases, the purchase price per share is described as a stated percentage of the fund’s net asset value per share as of a specified date, such as 98% or 99.5% of net asset value, determined in relation to the close of regular trading on the New York Stock Exchange on a designated day.
• Where can investors find official documents related to BMEZ?
  BlackRock’s press releases state that annual and semi‑annual reports and other regulatory filings for BlackRock Health Sciences Term Trust are available on the SEC’s website. Tender offer materials, such as the offer to purchase and related documents, are also filed with the SEC and can be obtained there.
• How does BlackRock describe its role with respect to BMEZ?
  In its press materials, BlackRock describes itself as a fiduciary to investors and as the investment advisor to the fund. It notes that it updates performance and certain other data for the fund on a monthly basis and that it manages the fund within the framework of its investment objectives and applicable regulations.